KPL-301 for Subjects With Giant Cell Arteritis

Status Completed

Clinical Trial Summary

The primary objective of the study is to evaluate the efficacy of mavrilimumab (KPL-301) versus placebo, co-administered with a 26-week corticosteroid taper, for maintaining sustained remission for 26 weeks in subjects with new onset or relapsing/refractory giant cell arteritis (GCA).

Clinical Trial Description

This Phase 2 randomized, double-blind, placebo-controlled proof of concept study will evaluate the efficacy and safety of mavrilimumab co-administered with a 26-week corticosteroid taper in subjects with GCA. The study will consist of a screening period (up to 6 weeks), a 26-week double-blind placebo-controlled period during which subjects will receive blinded mavrilimumab or placebo co-administered with a 26-week corticosteroid taper, and a 12-week washout safety follow-up period during which subjects will discontinue and wash off blinded mavrilimumab or placebo. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03827018
Study type	Interventional
Source	Kiniksa Pharmaceuticals, Ltd.
Contact
Status	Completed
Phase	Phase 2
Start date	September 20, 2018
Completion date	November 25, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03812302` - Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA)	Phase 2
Recruiting	`NCT02257866` - Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Recruiting	`NCT04888221` - Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement	Phase 3
Recruiting	`NCT05380453` - Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission	Phase 3
Recruiting	`NCT02333708` - Study of Circulating Microparticles in Giant Cell Arteritis
Completed	`NCT01450137` - Tocilizumab for Patients With Giant Cell Arteritis	Phase 2
Active, not recruiting	`NCT04519580` - Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
Recruiting	`NCT04239196` - Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA	Phase 2
Recruiting	`NCT06460142` - Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
Completed	`NCT03202368` - An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)	Phase 3
Not yet recruiting	`NCT02523625` - Giant Cell Arteritis: Improving Use of Ultrasound Evaluation	N/A
Completed	`NCT03285945` - FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment	N/A
Completed	`NCT02190916` - Vasculitis Illness Perception (VIP) Study	N/A
Recruiting	`NCT01241305` - One-Time DNA Study for Vasculitis
Terminated	`NCT02531633` - Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis	Phase 3
Completed	`NCT03765424` - Evaluation of Ultrasound and PET/CT in the Diagnosis and Monitoring of Giant Cell Arteritis
Completed	`NCT03409913` - Diagnostic Accuracy of FDG PET/CT of Cranial Arteries in GCA	N/A
Completed	`NCT01910038` - Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.	Phase 2
Not yet recruiting	`NCT04012905` - Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering	Phase 3
Recruiting	`NCT06004154` - Post-therapeutic Imaging Evaluation of Patients With Horton's Disease (Giant Cell Arteritis) (EvHortim)